Association of KCNQ1 polymorphisms with gliclazide efficacy in Chinese type 2 diabetic patients.

Fangfang Duan,Yali Guo,Liuwei Zhang,Peixian Chen,Xiaozhu Wang,Zhike Liu,Yonghua Hu,Shenren Chen,Dafang Chen
DOI: https://doi.org/10.1097/FPC.0000000000000204
2016-01-01
Pharmacogenetics and Genomics
Abstract:ObjectivesTo investigate the effects of KCNQ1 polymorphisms on the efficacy of gliclazide in type 2 diabetic patients.Materials and methodsA total of 443 newly diagnosed type 2 diabetic patients were included in this study. After enrollment, patients went on an 8-week gliclazide monotherapy. Fasting plasma glucose (FPG) was measured before and after the treatment. Life-style information was collected by weekly follow-up. Genotyping of the two single-nucleotide polymorphisms was performed using the single base primer extension method. T-test, one-way analysis of variance, and Pearson (2)-test were used to evaluate the effects of rs2237892 and rs2237897 on the FPG reduction and treatment success rate.ResultsAfter 8 weeks of gliclazide therapy, the FPG decreased significantly from 10.92.8 to 7.4 +/- 2.2mmol/l (P<0.001). Compared with the CC genotype, patients with CT or TT genotypes of rs2237897 achieved greater reduction in FPG (3.9 +/- 2.6 vs. 3.2 +/- 2.4mmol/l, P=0.003; 33.9 +/- 19.0 vs. 27.7 +/- 17.4%, P<0.001) and a higher rate of treatment success (74.1 vs. 65.2%, P=0.042 for criterion 1; 61.1 vs. 44.5%, P<0.001 for criterion 2, respectively), whereas no significant difference was found in the FPG reduction and treatment success rate among different genotypes of rs2237892.ConclusionOur results indicated that a common variant of KCNQ1, rs2237897, was associated with the efficacy of gliclazide after 8-week monotherapy in Chinese newly diagnosed type 2 diabetic patients. The FPG reduction and treatment success rate were significantly higher in carriers of CT and TT genotypes.
What problem does this paper attempt to address?